@prefix this: . @prefix sub: . @prefix np: . @prefix dct: . @prefix rdf: . @prefix nt: . @prefix xsd: . @prefix rdfs: . @prefix orcid: . @prefix bl: . @prefix nkg: . @prefix prov: . @prefix npx: . sub:Head { this: np:hasAssertion sub:assertion; np:hasProvenance sub:provenance; np:hasPublicationInfo sub:pubinfo; a np:Nanopublication . } sub:assertion { bl:category bl:Disease . sub:association rdf:object ; rdf:predicate bl:treats; rdf:subject ; a rdf:Statement; rdfs:label "brimonidine tartrate ophthalmic solution 2 is indicated for lowering intraocular pressure iop in patients with open angle glaucoma or ocular hypertension the iop lowering efficacy of brimonidine tartrate ophthalmic solution diminishes over time in some patients this loss of effect appears with a variable time of onset in each patient and should be closely monitored brimonidine tartrate ophthalmic solution 2 is an alpha adrenergic agonist indicated for lowering intraocular pressure iop in patients with open angle glaucoma or ocular hypertension 1"; bl:association_type bl:ChemicalToDiseaseOrPhenotypicFeatureAssociation; bl:provided_by ; bl:relation nkg:SymptomaticReliefIndication . bl:category bl:Drug . } sub:provenance { sub:assertion prov:wasAttributedTo orcid:0000-0002-1468-3557 . } sub:pubinfo { sub:sig npx:hasAlgorithm "RSA"; npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB"; npx:hasSignature "EqYUYVwpVNOxvbwCXyqfXwbx5yEghlnNGvJTws+02x6ovYy+bgnWRp3myIc/nExV6gpAr4RVQAc0HwbdnNAICYU/wpr5WcymiMX/dNnGD7QygRs3EPUjXMfA1eKHoaW7gPGkCrsYRQ7kveQMrY5NuYNbdEXJPuK2Uow/1LtDaaI="; npx:hasSignatureTarget this: . this: dct:created "2021-06-13T12:21:17.724+02:00"^^xsd:dateTime; dct:creator orcid:0000-0002-1468-3557; nt:wasCreatedFromProvenanceTemplate ; nt:wasCreatedFromPubinfoTemplate ; nt:wasCreatedFromTemplate . }